Heart disease is the leading cause of death for Americans. Kaiser Permanente Washington Health Research Institute (KPWHRI) scientists are working to understand how to reduce our risk of heart attacks, stroke, and other cardiovascular diseases throughout life.
Addressing risk factors, improving diagnosis, and exploring how medications, genes, and everyday life affect our cardiovascular health at different ages and stages are central to this work — as is translating research findings into practical, personalized care.
“We’ve found that helping patients and health care teams work together on personalized care plans is the best path to lifelong heart health,” says Beverly Green, MD, MPH, whose recent work has focused on improving the diagnosis of high blood pressure.
Additional focus areas for KPWHRI scientists include exploring the impact of cardiovascular diseases on other health conditions — and vice versa. Recently, this has led researchers Sascha Dublin, MD, PhD, and Laura B. Harrington, PhD, MPH, to investigate the impact of COVID-19 on cardiovascular health.
Below are other research highlights from KPWHRI’s cardiovascular health scientists (please visit their bios to learn more):
Arterburn DE, Richardson WS. Evidence-based case report: Should we look further for cancer in this patient with venous thromboembolism? West J Med. 2000;172:325-8. PubMed
Grayston JT, Jackson LA, Kennedy WJ, Kronmal RA. Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae-design issues. Am Heart J. 1999;138(5 Pt 2):S545-9. PubMed
Smith NL, Reiber GE, Psaty BM, Heckbert SR, Siscovick DS, Ritchie JL, Every NR, Koepsell TD. Trends in the post-hospitalization medical treatment of unstable angina pectoris: 1990 to 1995. Am J Cardiol. 1999;84(6):632-8. PubMed
Psaty BM, Furberg CD. British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity. BMJ. 1999;319(7210):589-90. PubMed
Jackson LA, Stewart DK, Wang SP, Cooke DB, Cantrell T, Grayston JT. Safety and effect on anti-Chlamydia pneumoniae antibody titers of a one-month course of daily azithromycin among adults with coronary artery disease. J Antimicrob Chemother. 1999;44(3):411-4. PubMed
Sascha Dublin, MD, PhDSenior Investigator |
Beverly B. Green, MD, MPHSenior Investigator |
Laura Harrington, PhD, MPHAssistant Investigator |
Ellen O'Meara, PhDPrincipal Collaborative Scientist |
Nicole M. Gatto, PhD, MPHPrincipal Collaborative Scientist |
Meagan C. Brown, PhD, MPHAssistant Investigator |
James Floyd, MD, MS
Assistant Professor, Department of Medicine
Adjunct Assistant Professor, Department of Epidemiology
University of Washington
Susan Heckbert, MD, PhD
University of Washington (UW) Department of Epidemiology; UW Cardiovascular Health Research Unit
Nicholas L. Smith, PhD, MPH
UW Professor, Epidemiology, Cardiovascular Health Research Unit
Director, Seattle Epidemiology and Information Resource Center, VA Puget Sound Health Care System